SILBER ALLAN C

SEC source: 0001104659-23-129767 · tm2333785-1_4seq1.xml · derivative · entry 8

SILBER ALLAN C · CIK 0001009161 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 537,322 shares

Expires 2029-03-28

F5 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

SEC source: 0001104659-23-129767 · tm2333785-1_4seq1.xml · derivative · entry 7

SILBER ALLAN C · CIK 0001009161 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 332,476 shares

Expires 2028-03-29

F5 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

SEC source: 0001104659-23-129767 · tm2333785-1_4seq1.xml · derivative · entry 6

SILBER ALLAN C · CIK 0001009161 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,787 shares

Expires 2026-03-25

F5 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

SEC source: 0001104659-23-129767 · tm2333785-1_4seq1.xml · nonDerivative · entry 5

SILBER ALLAN C · CIK 0001009161 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

F4 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the Reporting Person.

SEC source: 0001104659-23-129767 · tm2333785-1_4seq1.xml · nonDerivative · entry 4

SILBER ALLAN C · CIK 0001009161 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · Silber Holdings, Inc.

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

F3 · ownership.nature: Silber Holdings, Inc. is a corporation controlled by the Reporting Person.

SEC source: 0001104659-23-129767 · tm2333785-1_4seq1.xml · nonDerivative · entry 3

SILBER ALLAN C · CIK 0001009161 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · Trustee

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

F2 · ownership.nature: Held in a trust for which the Reporting Person is the trustee.

SEC source: 0001104659-23-129767 · tm2333785-1_4seq1.xml · nonDerivative · entry 2

SILBER ALLAN C · CIK 0001009161 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

SEC source: 0001104659-23-129767 · tm2333785-1_4seq1.xml · nonDerivative · entry 1

SILBER ALLAN C · CIK 0001009161 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · Personal Holding Company

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

SEC source: 0001104659-23-115374 · tm2330145-1_4seq1.xml · nonDerivative · entry 3

SILBER ALLAN C · CIK 0001009161 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · Trustee

Disclosed balance after: 38,087

F1 · kind: Reflects the gift of common stock to a charitable donor-advised fund.

F2 · ownership.nature: Held in a trust for which the Reporting Person is the trustee.

SEC source: 0001104659-23-039363 · tm2311087-6_4seq1.xml · derivative · entry 1

SILBER ALLAN C · CIK 0001009161 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 537,322

Underlying: Common Stock · 537,322 shares

Expires 2029-03-28

F1 · derivative.exercise_date: The option vests 25% on the first anniversary of the date of grant with the remaining 75% vesting in three equal annual installments thereafter.

SEC source: 0001104659-22-120873 · tm2231115-1_4seq1.xml · nonDerivative · entry 2

SILBER ALLAN C · CIK 0001009161 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,268,605

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.20 to $6.60, inclusive. The Reporting Person undertakes to provide to POINT Biopharma Global Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001104659-22-120873 · tm2231115-1_4seq1.xml · nonDerivative · entry 1

SILBER ALLAN C · CIK 0001009161 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,246,208

SEC source: 0001104659-22-041129 · tm2211101-4_4seq1.xml · derivative · entry 1

SILBER ALLAN C · CIK 0001009161 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 332,476

Underlying: Common Stock · 332,476 shares

Expires 2028-03-29

F1 · derivative.exercise_date: The option vests 25% on the first anniversary of the date of grant with the remaining 75% vesting in three equal annual installments thereafter.

SEC source: 0001209191-21-054826 · doc4.xml · nonDerivative · entry 2

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,198,296

F2 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-054826 · doc4.xml · nonDerivative · entry 1

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,223,518

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.14, inclusive. The reporting person undertakes to provide to Heritage Global Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-054120 · doc4.xml · nonDerivative · entry 3

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,251,763

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.17, inclusive.

F2 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-054120 · doc4.xml · nonDerivative · entry 2

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,267,037

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.20 to $2.25, inclusive.

F2 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-054120 · doc4.xml · nonDerivative · entry 1

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,273,518

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.14, inclusive. The reporting person undertakes to provide to Heritage Global Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4.

F2 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-053540 · doc4.xml · nonDerivative · entry 3

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,322,864

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.13 to $2.17, inclusive.

F2 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-053540 · doc4.xml · nonDerivative · entry 2

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,352,026

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $2.04, inclusive.

F2 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-053540 · doc4.xml · nonDerivative · entry 1

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,435,539

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.85, inclusive. The reporting person undertakes to provide to Heritage Global Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4.

F2 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-052825 · doc4.xml · nonDerivative · entry 1

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,478,026

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.78 to $1.84, inclusive. The reporting person undertakes to provide to Heritage Global Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-052013 · doc4.xml · nonDerivative · entry 1

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,559,426

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $1.91, inclusive. The reporting person undertakes to provide to Heritage Global Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001104659-21-087833 · tm2121126-20_4seq1.xml · derivative · entry 5

SILBER ALLAN C · CIK 0001009161 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,787

Underlying: Common Stock · 6,787 shares

Expires 2026-03-25

F5 · kind: At the effective time of the Business Combination, each option to acquire shares of Old POINT was exchanged for an option to acquire shares of Common Stock of the Issuer based on an implied Old POINT vested equity value of $585,000,000. As a result, the Reporting Person received the reported options to acquire the Issuer's Common Stock in consideration for the options to acquire equity securities of Old POINT held by the Reporting Person prior to the Business Combination.

F6 · derivative.exercise_date: The option vested 25% on March 18, 2021 with the remaining 75% vesting in three equal annual installments thereafter.

SEC source: 0001104659-21-087833 · tm2121126-20_4seq1.xml · nonDerivative · entry 4

SILBER ALLAN C · CIK 0001009161 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 71,744

F1 · price: On June 30, 2021, POINT BIOPHARMA GLOBAL INC. (f/k/a Therapeutics Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which RACA, Bodhi Merger Sub, Inc., a wholly-owned subsidiary of the Issuer merged with and into POINT Biopharma Inc., ("Old POINT"). At the effective time of the Business Combination, each share of Old POINT outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Old POINT vested equity value of $585,000,000. As a result, the Reporting Person received the reported shares of the Issuer's Common Stock in consideration for the equity securities of Old POINT held by the Reporting Person prior to the Business Combination.

F4 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the Reporting Person.

SEC source: 0001104659-21-087833 · tm2121126-20_4seq1.xml · nonDerivative · entry 3

SILBER ALLAN C · CIK 0001009161 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Silber Holdings, Inc.

Disclosed balance after: 4,035,655

F1 · price: On June 30, 2021, POINT BIOPHARMA GLOBAL INC. (f/k/a Therapeutics Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which RACA, Bodhi Merger Sub, Inc., a wholly-owned subsidiary of the Issuer merged with and into POINT Biopharma Inc., ("Old POINT"). At the effective time of the Business Combination, each share of Old POINT outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Old POINT vested equity value of $585,000,000. As a result, the Reporting Person received the reported shares of the Issuer's Common Stock in consideration for the equity securities of Old POINT held by the Reporting Person prior to the Business Combination.

F3 · ownership.nature: Silber Holdings, Inc is a corporation controlled by Reporting Person.

SEC source: 0001104659-21-087833 · tm2121126-20_4seq1.xml · nonDerivative · entry 2

SILBER ALLAN C · CIK 0001009161 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trustee

Disclosed balance after: 538,087

F1 · price: On June 30, 2021, POINT BIOPHARMA GLOBAL INC. (f/k/a Therapeutics Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which RACA, Bodhi Merger Sub, Inc., a wholly-owned subsidiary of the Issuer merged with and into POINT Biopharma Inc., ("Old POINT"). At the effective time of the Business Combination, each share of Old POINT outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Old POINT vested equity value of $585,000,000. As a result, the Reporting Person received the reported shares of the Issuer's Common Stock in consideration for the equity securities of Old POINT held by the Reporting Person prior to the Business Combination.

F2 · ownership.nature: Held in a trust in which the Reporting Person is the Trustee

SEC source: 0001104659-21-087833 · tm2121126-20_4seq1.xml · nonDerivative · entry 1

SILBER ALLAN C · CIK 0001009161 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,218,605

F1 · price: On June 30, 2021, POINT BIOPHARMA GLOBAL INC. (f/k/a Therapeutics Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which RACA, Bodhi Merger Sub, Inc., a wholly-owned subsidiary of the Issuer merged with and into POINT Biopharma Inc., ("Old POINT"). At the effective time of the Business Combination, each share of Old POINT outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Old POINT vested equity value of $585,000,000. As a result, the Reporting Person received the reported shares of the Issuer's Common Stock in consideration for the equity securities of Old POINT held by the Reporting Person prior to the Business Combination.

SEC source: 0001209191-21-044847 · doc4.xml · nonDerivative · entry 6

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,561,926

F1 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-044847 · doc4.xml · nonDerivative · entry 5

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,562,177

F1 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-044847 · doc4.xml · nonDerivative · entry 4

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,562,277

F1 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-044847 · doc4.xml · nonDerivative · entry 3

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,562,288

F1 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-044847 · doc4.xml · nonDerivative · entry 2

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,562,388

F1 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-044847 · doc4.xml · nonDerivative · entry 1

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,562,588

F1 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001104659-22-023334 · tm226751-1_5seq1.xml · nonDerivative · entry 2

SILBER ALLAN C · CIK 0001009161 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Trustee

Disclosed balance after: 514,778

F2 · kind: On June 30, 2021, the Reporting Person, as trustee, distributed 23,309 shares of the Issuer's Common Stock held pursuant to a trust to certain beneficiaries of that trust. This disposition was inadvertently omitted from the Form 4 filed by the Reporting Person on June 30, 2021.

F3 · ownership.nature: Held in a trust for which the Reporting Person is the trustee.

SEC source: 0001104659-22-023334 · tm226751-1_5seq1.xml · nonDerivative · entry 1

SILBER ALLAN C · CIK 0001009161 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 313,884

F1 · price: On June 30, 2021, POINT Biopharma Global Inc. (f/k/a Therapeutics Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which Bodhi Merger Sub, Inc., a wholly-owned subsidiary of the Issuer, merged with and into POINT Biopharma Inc. ("Old POINT"). At the effective time of the Business Combination, each share of Old POINT outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Old POINT vested equity value of $585,000,000. As a result, the Reporting Person's spouse received the reported shares of the Issuer's Common Stock in consideration for the equity securities of Old POINT held by the Reporting Person's spouse prior to the Business Combination. These shares held by the Reporting Person's spouse were inadvertently omitted from the Form 4 filed by the Reporting Person on June 30, 2021.

SEC source: 0001209191-21-031774 · doc4.xml · nonDerivative · entry 24

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,562,607

F4 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-031774 · doc4.xml · nonDerivative · entry 23

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,562,707

F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.01, inclusive.

F4 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-031774 · doc4.xml · nonDerivative · entry 22

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,587,107

F4 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-031774 · doc4.xml · nonDerivative · entry 21

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,604,697

F4 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-031774 · doc4.xml · nonDerivative · entry 20

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,607,625

F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.02, inclusive.

F4 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-031774 · doc4.xml · nonDerivative · entry 19

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,616,658

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $2.96, inclusive.

F4 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-031774 · doc4.xml · nonDerivative · entry 18

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,627,678

F4 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-031774 · doc4.xml · nonDerivative · entry 17

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,629,183

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $2.97, inclusive.

F4 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-031774 · doc4.xml · nonDerivative · entry 16

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Anglian Holdings, LLC

Disclosed balance after: 3,657,862

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $2.99, inclusive.

F4 · ownership.nature: Anglian Holdings, LLC is a limited liability company solely owned by the reporting person.

SEC source: 0001209191-21-031774 · doc4.xml · derivative · entry 31

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F16 · derivative.exercise_date: Options originally vested 25% annually beginning on the first anniversary of the grant date. Unvested options accelerated on the reporting person's resignation as a director.

SEC source: 0001209191-21-031774 · doc4.xml · derivative · entry 30

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2026-12-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F16 · derivative.exercise_date: Options originally vested 25% annually beginning on the first anniversary of the grant date. Unvested options accelerated on the reporting person's resignation as a director.

SEC source: 0001209191-21-031774 · doc4.xml · derivative · entry 29

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2027-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F16 · derivative.exercise_date: Options originally vested 25% annually beginning on the first anniversary of the grant date. Unvested options accelerated on the reporting person's resignation as a director.

SEC source: 0001209191-21-031774 · doc4.xml · derivative · entry 28

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2028-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F16 · derivative.exercise_date: Options originally vested 25% annually beginning on the first anniversary of the grant date. Unvested options accelerated on the reporting person's resignation as a director.

SEC source: 0001209191-21-031774 · doc4.xml · derivative · entry 27

SILBER ALLAN C · CIK 0001009161 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2029-03-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F16 · derivative.exercise_date: Options originally vested 25% annually beginning on the first anniversary of the grant date. Unvested options accelerated on the reporting person's resignation as a director.